BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)

BAY 2253651 is a nasally applied genioglossus muscle activator via pharyngeal mucosal receptor stimulation (potassium channel blocker) aimed to treat obstructive sleep apnoea. Although well-tolerated and safe, there was no significant therapeutic effect. https://bit.ly/3zDbyia

Detalles Bibliográficos
Autores principales: Gaisl, Thomas, Turnbull, Chris D., Weimann, Gerrit, Unger, Sigrun, Finger, Rudolf, Xing, Charles, Cistulli, Peter A., West, Sophie, Chiang, Alan K.I., Eckert, Danny J., Stradling, John R., Kohler, Malcolm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607905/
https://www.ncbi.nlm.nih.gov/pubmed/34531274
http://dx.doi.org/10.1183/13993003.01937-2021
Descripción
Sumario:BAY 2253651 is a nasally applied genioglossus muscle activator via pharyngeal mucosal receptor stimulation (potassium channel blocker) aimed to treat obstructive sleep apnoea. Although well-tolerated and safe, there was no significant therapeutic effect. https://bit.ly/3zDbyia

Ejemplares similares